您好，非常感谢您对公司的关注。关于公司承诺情况，请您查阅公司相关公告。谢谢！查看更多董秘问 答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 投资者提问： 你公司实施30亿定增已3年多，这3年公司收益逐年下降至主业亏损，请问定增何时才能带来主业的收 益？针对定增，公司业绩承诺是什么？ 董秘回答(泰和新材SZ002254)： ...

耀皮玻璃关于向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告 上海耀皮玻璃集团股份有限公司于近日收到中国证券监督管理委员会出具的《关于同意上海耀皮玻璃集 团股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕2520号），同意公司向特定对象 发行股票的注册申请。批复自同意注册之日起12个月内有效。公司应严格按照报送上海证券交易所的申 报文件和发行方案实施发行。在发行过程中如发生重大事项，需及时报告并按规定处理。公司董事会将 根据批复要求及股东会授权，在规定期限内办理相关事宜，并履行信息披露义务。 耀皮玻璃2025年度向特定对象发行A股股票证券募集说明书（注册稿） 上海耀皮玻璃集团股份有限公司拟向特定对象发行A股股票，募集资金总额不超过30,000.00万元，用于 大连耀皮熔窑节能升级及浮法玻璃生产线自动化改造项目、天津耀皮产线节能升级及镀膜工艺改造项目 及补充流动资金。本次发行已获董事会、股东大会审议通过，并取得国资监管部门批复及中国证监会同 意注册。发行对象为不超过35名符合条件的特定投资者，发行价格不低于定价基准日前20个交易日公司 股票交易均价的80%。 截至2025年11 ...

Core Points - The stock price of Zhejiang Biyi Electric Co., Ltd. (比依股份) has decreased by 9.16% from 20.63 yuan to 18.74 yuan as of November 21, 2025 [1] - The company has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors, with a total fundraising amount not exceeding 482.47 million yuan [2][4] - The company plans to use the raised funds for the construction of a smart kitchen appliance project, specifically the second phase of the China-Italy Industrial Park [2] - The total share capital of the company has been adjusted from 187,947,951 shares to 187,939,551 shares due to the repurchase and cancellation of restricted stock [3] Company Announcements - The company has received approval for the issuance of A-shares to specific investors, with a fundraising target of up to 482.47 million yuan for the smart kitchen appliance project [2][4] - The maximum number of shares to be issued has been adjusted to not exceed 56,381,865 shares due to the cancellation of certain restricted shares [3][4] - The issuance will involve no more than 30% of the total share capital prior to the issuance and will be limited to 35 specific investors [2]

公司于2025年11月19日召开第十届董事会第十三次会议，会议审议通过了《关于终止2025年度向特定对 象发行A股股票事项并撤回申请文件的议案》，同意公司终止本次向特定对象发行股票事项并申请撤回 申请文件。 江苏索普2025年10月25日披露的2025年度向特定对象发行A股股票募集说明书(申报稿)显示，本次向特 定对象发行股票的募集资金总额不超过150,000.00万元(含本数)，扣除发行费用后的募集资金净额将用 于如下项目：醋酸乙烯及EVA一体化项目(一期工程)。 | 房号 | 项目名称 | 项目总投资 | 拟投入募集资金 | | --- | --- | --- | --- | | | 醋酸乙烯及 EVA一体化项目(一期工程) | 322,592.14 | 150.000.00 | | | 合计 | 322,592.14 | 150,000.00 | 本次发行面向符合中国证监会规定的投资者，截至募集说明书签署日，本次发行尚未确定发行对象，因 而无法确定发行对象与公司的关系。 截至募集说明书签署日，公司总股本为1,167,842,884股，索普集团持有公司876,653,001股，占公司总股 本的75.07% ...

Core Viewpoint - Lingyun Technology Co., Ltd. has completed its response to the Shanghai Stock Exchange's inquiry regarding its application for a specific stock issuance for the year 2024, but the implementation is subject to further review and approval by the exchange and the China Securities Regulatory Commission [1] Group 1 - The company received an inquiry letter from the Shanghai Stock Exchange on October 31, 2025, regarding its application for a specific stock issuance [1] - Following the receipt of the inquiry letter, the company, along with relevant intermediaries, conducted thorough research and addressed each question raised [1] - The implementation of the stock issuance is contingent upon the review process by the Shanghai Stock Exchange and the approval from the China Securities Regulatory Commission, indicating uncertainty in the outcome [1]

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has announced the termination of its plan to issue shares to specific investors due to significant opposition from its major shareholder, Genie Pharma, which may impact the company's stable operations [1][4]. Group 1: Share Issuance and Opposition - The company initially planned to issue 163,901,373 shares to Nanjing Haiqing Pharmaceutical Co., Ltd. to raise 1.033 billion yuan for daily R&D and operational expenses, which would have resulted in a change of control [2]. - The board approved the share issuance plan, but it did not receive unanimous support, with board member Zhao Yachao voting against it [2][3]. - Zhao Yachao's opposition was based on the lack of thorough investigation into other potential investors, concerns about Haiqing Pharmaceutical's lack of experience in the infection field, and the vague use of raised funds [3]. Group 2: Financial Performance and Challenges - Mengke Pharmaceutical has only one commercialized product, Kantizolam, and has not yet achieved profitability, with revenues of 48.21 million yuan in 2022, 90.78 million yuan in 2023, and projected revenues of 130 million yuan in 2024 [5]. - The company has experienced significant losses, with net profits of -220 million yuan in 2022 and -194 million yuan in the first nine months of 2025 [5]. - The company's debt-to-asset ratio has increased rapidly, reaching 64.57% by the end of September 2025, indicating growing financial pressure [6]. Group 3: Future Considerations - The termination of the share issuance raises questions about how the company will address its production and R&D shortfalls and alleviate financial pressure moving forward [6].

11月18日晚间，四川汇源光通信股份有限公司（以下简称"汇源通信（000586）"，证券代码：000586） 发布定增预案，拟向特定对象发行A股股票募集资金不超6.1亿元，扣除发行费用后将全部用于补充流动 资金。 2024年1月，由于汇源通信原第一大股东广州蕙富骐骥投资合伙企业（有限合伙）的股权被拍卖，公司 进入无控股股东、无实际控制人状态。此次定增发行后，鼎耘产业将成为公司控股股东，李红星将正式 出任实际控制人。 公开信息显示，李红星目前参股并担任执行董事的北京鼎耘科技发展有限公司（简称"鼎耘科技"）持有 汇源通信2727.33万股股份，占公司现有总股本的14.1%。同时，李红星作为鼎耘产业的实际控制人，还 担任合肥鼎耘工业智能科技有限公司（系鼎耘产业的执行事务合伙人）的董事。因此，鼎耘科技与鼎耘 产业确认双方构成一致行动人。 汇源通信主营业务为电力光缆和电力系统在线监测，主要为国家电网、南方电网等公司提供定制化光缆 产品。在电力系统在线监测领域，该公司已发展成为国内高压输电线路在线监测产品的主力供应商之 一。 汇源通信在预案中提及，依托长期耕耘电力系统奠定的市场地位与客户信任度，以及在塑料光纤领域的 技术 ...

Core Points - Company Keda Xunfei has completed the response to the Shenzhen Stock Exchange's inquiry regarding the issuance of A-shares to specific investors for the year 2025, and has updated the fundraising prospectus accordingly [1][2] - The company emphasizes that the issuance is subject to approval from the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission, indicating uncertainty regarding the final implementation [1][2] Group 1 - The company received the inquiry letter from the Shenzhen Stock Exchange on October 24, 2025, and has addressed the questions raised in the letter [1] - The updated fundraising documents include the latest financial data from the company's third-quarter report disclosed on October 21, 2025 [1] - The updated documents were officially disclosed on November 15, 2025, on the Giant Tide Information Network [1] Group 2 - The company clarifies that the issuance of A-shares requires approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission, with no guaranteed timeline for these processes [2] - Investors are advised to make cautious decisions due to the uncertainties surrounding the approval and registration processes [2]

Core Points - Yonghui Supermarket disclosed a share reduction plan by major shareholders, including Chairman Zhang Xuansong and associated funds, intending to reduce up to 90,750,000 shares, representing 1% of the total share capital [1][2] - The total shares held by Zhang Xuansong and associated funds amount to 1,274,987,806 shares, which is 14.05% of the company's total share capital [1] - The planned reduction is expected to generate approximately 430 million yuan based on the closing price of 4.74 yuan per share on November 11 [3] Shareholding Structure - Zhang Xuansong directly held 1,407,250,222 shares, or 14.79% of the total share capital, before the planned reduction [3] - The associated funds include multiple private equity funds managed by Shanghai Xishirun Investment Management Co., Ltd., which collectively hold significant shares [1] Financial Performance - Yonghui Supermarket reported net losses over the past four years, totaling 10.211 billion yuan, with annual losses of -39.44 billion yuan in 2021, -27.63 billion yuan in 2022, -13.29 billion yuan in 2023, and -14.65 billion yuan in 2024 [4] - The company's total revenue has declined from 910.6 billion yuan in 2021 to 675.7 billion yuan in 2022, indicating a downward trend in financial performance [5] Fundraising Plans - The company plans to raise up to 311.39 million yuan through a private placement, with funds allocated for store upgrades, logistics improvements, and working capital [6][7] - The total investment for the store upgrade project is approximately 397.93 million yuan, while logistics upgrades are estimated at 30.90 million yuan [6] Governance Structure - As of the latest reports, Yonghui Supermarket has no controlling shareholder or actual controller, with the largest shareholder, Jun Cai International, holding 29.40% of the shares [7] - The company maintains a governance structure without a controlling shareholder, ensuring stability in its management [7][8]

根据中国证券监督管理委员会《关于核准上海晶华胶粘新材料股份有限公司非公开发行股票的批复》(证监许可 [2023]247号)，并经上海证券交易所同意，公司本次向特定对象发行股票数量为44,062,929股，每股面值为人民币1.00 元，发行价格为人民币9.90元/股，此次发行募集资金总额为人民币436,222,997.10元，扣除本次发行费用12,264,335.45 元(不含增值税)后，募集资金净额为423,958,661.65元。天衡会计师事务所(特殊普通合伙)于2023年7月19日出具了《验 资报告》(天衡验字(2023)00093号)，经审验，本次发行的募集资金已全部到位。公司已对募集资金实行了专户存储制 度，并与实施主体、开户银行、保荐机构签订了《募集资金专户存储三/四方监管协议》，上述募集资金已全部存放于 募集资金专户进行管理。2023年7月18日，光大证券股份有限公司已将本次发行募集资金扣除承销保荐费用人民币 8,350,195.56元(含税)后的余款人民币427,872,801.54元，汇入公司在上海农村商业银行永丰支行开立的账户。 根据中国证券监督管理委员会《关于同意上海晶华胶粘新材料股份有限 ...